Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impedance Cardiography to Decrease Preeclampsia Risk in Obese Patients
NCT03105661Phase 1Unknown
- Sponsor
- University of Tennessee Graduate School of Medicine
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of labetalol, nifedipine and atenolol in preeclampsia, sponsored by University of Tennessee Graduate School of Medicine. Primary endpoint: Rates of preeclampsia at 2 years. Status: unknown.
02
Drugs
labetalolnifedipineatenolol
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT03105661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105661.